An ORR of 24.6% was observed but EBV-positive and MSI-H patients obtained dramatic responses to pembrolizumab (ORR, respectively, of 85.7% and 100%), furthermore activity was significantly higher in PDL-1 positive cancer (cut-off ≥ 1) when compared to PDL-1 negative (ORR of 50.0% versus 0.0%, p ≤ 0.001). The gene discussed is CD274; the disease is cancer.